

Patient Name : Mr MR.DUMMY

DOB/Age/Gender : 23 Y/Male

Patient ID / UHID : 8052560/RCL7249178

Referred By : Dr. X

Sample Type : Serum

Sample Collected : Apr 26, 2024, 01:00 PM

Report Date : May 25, 2024, 02:48 PM.

Barcode No : SI485314

Report Status : Final Report

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

SS-A / Ro Antibody

SSA - A (Soluble Substance A) IgG EIA, SERUM	11.6	AU/ml	NEGATIVE: < 12 EQUIVOCAL: 12-18 POSITIVE: > 18
---	------	-------	--

Interpretation:

SS-A is a RNA protein particle (ribonucleoprotein, RNP) ubiquitously distributed in all tissues. It is composed of two proteins (60 kDa and 52 kDa) associated with at least four small uridine-rich cytoplasmic RNAs (hyRNA, human cytoplasmic RNA), its function is yet unknown. Autoantibodies against SS-A (formerly named Ro after prototype patient Robert) as well as SS-B named La after prototype patient Lane) are typical markers for Sjögren's syndrome (SS) and systemic lupus erythematosus (SLE), both are systemic autoimmune diseases of unknown etiology and female predominance. Sjögren's syndrome is a disorder affecting exocrine glands such as lacrimal and salivary glands. Chronic inflammation dominated by plasmacells results in a progressive loss of function of these glands, described as Sicca syndrome. The diagnosis of SS is based on testing for loss of excretory function in eye and salivary glands and the detection of anti-SS-A and anti-SS-B antibodies. Antibodies against both 60 kDa and 52 kDa SS-A proteins are found in 70-80% of patients with primary SS, 40-94% of these patients display antibodies against the SS-B/La antigen, additionally. SS-A antibodies occur in 25-40% of patients with ANA-positive SLE (ANA: anti- nuclear antibodies), as well as isolated in 65% of patients with subacute cutaneous LE. Both anti-SS-A and anti-SS-B antibodies are associated with congenital heartblock. Isolated detection of 52 kDa Ss-A antibodies without 60 kDa antigen, is found more often in SS, as well as in ANA-negative LE and with a frequency of 95% in neonatal LE.

*** End Of Report ***

Disclaimer: Method given in report are only indicative and can be changed depending upon type of machine and kit available at time of testing.

Not all tests at all locations are under NABL scope. Availability of tests under NABL scope varies from lab to lab.



Booking Centre :- DEMO PARTNER CHENNAI, DEMO PARTNER CHENNAI

Processing Lab :-

 928-909-0609 ccsupport@redcliffelabs.com www.redcliffelabs.com

All Lab results are subject to clinical interpretation by qualified medical professional and this report is not subject to use for any medico-legal purpose.


Dr. Dummy

Terms and Conditions of Reporting

1. The presented findings in the Reports are intended solely for informational and interpretational purposes by the referring physician or other qualified medical professionals possessing a comprehensive understanding of reporting units, reference ranges, and technological limitations. The laboratory shall not be held liable for any interpretation or misinterpretation of the results, nor for any consequential or incidental damages arising from such interpretation.
2. It is to be presumed that the tests performed pertain to the specimen/sample attributed to the Customer's name or identification. It is presumed that the verification particulars have been cleared out by the customer or his/her representation at the point of generation of said specimen / sample. It is hereby clarified that the reports furnished are restricted solely to the given specimen only.
3. It is to be noted that variations in results may occur between different laboratories and over time, even for the same parameter for the same Customer. The assays are performed and conducted in accordance with standard procedures, and the reported outcomes are contingent on the specific individual assay methods and equipment(s) used, as well as the quality of the received specimen.
4. This report shall not be deemed valid or admissible for any medico-legal purposes.
5. The Customers assume full responsibility for apprising the Company of any factors that may impact the test finding. These factors, among others, includes dietary intake, alcohol, or medication / drug(s) consumption, or fasting. This list of factors is only representative and not exhaustive.

DISCLAIMER

This is a sample report provided for demonstration purposes only and does not represent an actual patient report. Test results, reference ranges, methodologies, instrumentation, and report formats may vary depending on the laboratory performing the test. The format and representation shown are indicative of reports generated by the National Reference Laboratory of Redcliffe Labs, Noida. This sample report should not be used for medical interpretation, diagnosis, or treatment decisions.